HomeAI · summaries
Storia in 4 fonti
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug -
Summit Therapeutics shares updated Phase 3 data, revealing improving overall survival trends for lung cancer therapy ivonescimab.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from…
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
- ·
endpoints.news
Summit reports two-year survival data for Western patients, though context lacking
